Realities of KRAS-mutated non-small cell lung cancer.
作者信息
Min Young Joo
机构信息
Division of Oncology, Department of Hematology and Oncology, Ulsan University Hospital, Ulsan, Korea.
出版信息
Korean J Intern Med. 2017 May;32(3):442. doi: 10.3904/kjim.2017.148. Epub 2017 Apr 28.
Abstract
摘要
相似文献
1
Realities of KRAS-mutated non-small cell lung cancer.KRAS 突变型非小细胞肺癌的现状
Korean J Intern Med. 2017 May;32(3):442. doi: 10.3904/kjim.2017.148. Epub 2017 Apr 28.
2
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.KRAS 突变在接受二线或三线化疗的晚期非小细胞肺癌患者中的预后作用
Anticancer Res. 2016 Mar;36(3):1077-82.
3
KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.在一线铂类化疗治疗的晚期非鳞状非小细胞肺癌患者中，KRAS 突变没有预测价值。
J Thorac Oncol. 2013 Sep;8(9):1190-5. doi: 10.1097/JTO.0b013e318298764e.
4
Treatment of KRAS-Mutant Non-Small Cell Lung Cancer: The End of the Beginning for Targeted Therapies.KRAS 突变型非小细胞肺癌的治疗：靶向治疗新纪元的开端
JAMA. 2017 May 9;317(18):1835-1837. doi: 10.1001/jama.2017.3436.
5
Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.靶向KRAS变体治疗非小细胞肺癌：潜在的治疗应用
Expert Rev Respir Med. 2016;10(1):53-68. doi: 10.1586/17476348.2016.1115349. Epub 2015 Nov 17.
6
CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.CHAMP：帕尼单抗联合培美曲塞和顺铂对比培美曲塞和顺铂治疗晚期原发性非鳞状非小细胞肺癌患者的II期研究，特别关注KRAS状态
Clin Lung Cancer. 2015 Nov;16(6):447-56. doi: 10.1016/j.cllc.2015.05.009. Epub 2015 Jun 2.
7
Dispensable role of CCL28 in Kras-mutated non-small cell lung cancer mouse models.CCL28在Kras突变的非小细胞肺癌小鼠模型中的非必需作用。
Acta Biochim Biophys Sin (Shanghai). 2020 Jun 20;52(6):691-694. doi: 10.1093/abbs/gmaa032.
8
Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.KRAS突变在接受免疫检查点抑制剂治疗的晚期非小细胞肺癌中的预后价值：一项荟萃分析与综述
Oncotarget. 2017 Jul 18;8(29):48248-48252. doi: 10.18632/oncotarget.17594.
9
Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.针对 KRAS 突变型非小细胞肺癌：一个充满失败的历史和充满希望的未来，对于一个多样化的实体来说。
Crit Rev Oncol Hematol. 2017 Feb;110:1-12. doi: 10.1016/j.critrevonc.2016.12.005. Epub 2016 Dec 9.
10
EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.HIV感染患者中非小细胞肺癌的表皮生长因子受体（EGFR）和 Kirsten 大鼠肉瘤病毒癌基因（KRAS）突变状态
Lung Cancer. 2016 Jun;96:74-7. doi: 10.1016/j.lungcan.2015.11.021. Epub 2015 Nov 28.
引用本文的文献
1
Comparison of PANAMutyper and PNAClamp for Detecting KRAS Mutations from Patients With Malignant Pleural Effusion.PANAMutyper与PNAClamp用于检测恶性胸腔积液患者KRAS突变的比较。
In Vivo. 2019 May-Jun;33(3):945-954. doi: 10.21873/invivo.11563.
本文引用的文献
1
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.KRAS G12C突变作为培美曲塞治疗非小细胞肺癌的不良预后标志物。
Korean J Intern Med. 2017 May;32(3):514-522. doi: 10.3904/kjim.2015.299. Epub 2017 Apr 14.
2
Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.针对 KRAS 突变型非小细胞肺癌：一个充满失败的历史和充满希望的未来，对于一个多样化的实体来说。
Crit Rev Oncol Hematol. 2017 Feb;110:1-12. doi: 10.1016/j.critrevonc.2016.12.005. Epub 2016 Dec 9.
Zotero 插件